Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway

Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions

(2014) Fang Wu et al.   PHARMACEUTICAL RESEARCH

Response to “Ethnic-Specific In Vitro–In Vivo Extrapolation and Physiologically Based Pharmacokinetic Approaches to Predict Cytochrome P450-Mediated Pharmacokinetics in Chinese Population: Opportunities and Challenges”

(2013) Zoe E. Barter et al.   CLINICAL PHARMACOKINETICS

Ethnic-Specific In Vitro–In Vivo Extrapolation and Physiologically Based Pharmacokinetic Approaches to Predict Cytochrome P450-Mediated Pharmacokinetics in the Chinese Population: Opportunities and Challenges

(2013) Guo-Fu Li et al.   CLINICAL PHARMACOKINETICS

Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling

(2013) Zoe E. Barter et al.   CLINICAL PHARMACOKINETICS

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review

(2012) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions

(2012) P Zhao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

(2011) Malcolm Rowland et al.   Annual Review of Pharmacology and Toxicology

Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes

(2011) Junling Yang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel

(2011) B. W. Ogilvie et al.   DRUG METABOLISM AND DISPOSITION

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

(2010) D J Angiolillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers

(2010) Yongqing Wang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Population-Based Mechanistic Prediction of Oral Drug Absorption

(2009) Masoud Jamei et al.   AAPS Journal

CYP2C19haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole

(2009) S. K. Jin et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

(2008) R. Michael Baldwin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Globalization of sponsored clinical trials

(2008) Johan P. E. Karlberg   NATURE REVIEWS DRUG DISCOVERY

Trends in the globalization of clinical trials

(2007) Fabio A. Thiers et al.   NATURE REVIEWS DRUG DISCOVERY